Recent Mergers & Acquisitions Revolution Medicines has been actively involved in M&A activities, such as acquiring Pharmatching GmbH and NS Healthcare, as well as being acquired by EQRx. These partnerships and acquisitions present potential sales opportunities to leverage combined resources and offerings.
Focus on RAS-Addicted Cancers With a focus on developing innovative therapies for RAS-addicted cancers, Revolution Medicines' expertise in this area presents a valuable opportunity for collaborations with hospitals, oncology centers, and research institutions specializing in treating such cancers.
Financial Stability & Funding Revolution Medicines' solid financial standing, with revenues between $50-100M and significant funding of $324M, indicates a strong position to invest in new technologies, expand market reach, and potentially partner with other companies for mutual growth.
Cutting-Edge Technology Stack Utilizing advanced technologies such as Varnish, Docker, and Microsoft tools, Revolution Medicines demonstrates a commitment to innovation and efficiency. Companies offering complementary tech solutions or services could explore collaboration opportunities with Revolution Medicines.
Strategic Board Appointments The appointment of Lorence Kim, M.D., to Revolution Medicines' board of directors signifies a strategic move to enhance expertise and guidance. Companies in healthcare consulting, strategic advisory services, or pharmaceutical governance could explore partnerships based on shared goals and vision.
Revolution Medicines uses 8 technology products and services including Varnish, Docker, Microsoft Excel, and more. Explore Revolution Medicines's tech stack below.
| Revolution Medicines Email Formats | Percentage |
| first@revolutionmedicines.com | 46% |
| flast@revolutionmedicines.com | 44% |
| first.last@revolutionmedicines.com | 6% |
| fl@revolutionmedicines.com | 2% |
| filast@revolutionmedicines.com | 1% |
| last@revolutionmedicines.com | 1% |
| fmiddlelast@revolutionmedicines.com | 0% |
| flast@revmed.com | 76% |
| first@revmed.com | 23% |
| last@revmed.com | 1% |
Biotechnology ResearchCalifornia, United States201-500 Employees
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.
Company Overview
Funding & FinancialsRevolution Medicines has raised a total of $324M of funding over 8 rounds. Their latest funding round was raised on Mar 02, 2023.
Revolution Medicines's revenue is in the range of $50M$100M
Funding & FinancialsRevolution Medicines has raised a total of $324M of funding over 8 rounds. Their latest funding round was raised on Mar 02, 2023.
Revolution Medicines's revenue is in the range of $50M$100M
Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.
1-888-653-2347 
support@leadiq.com